Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.67%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.